Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: InterMune | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: InterMune

Esbriet revenue up 204%

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

InterMune

4Q Revenues: $8.2 million (earnings were $2.7 million in 4Q11)

4Q Loss: $58.6 million (loss of $44.5 million in 4Q11)

FY Revenues: $26.2 million (earnings were $5.4 million FY11)

FY Loss: $150.1 million (loss of $154.8 million FY11)

Comments: Esbriet (pirfenidone) revenue in the quarter was $8.2 million, up 204%. Results in the quarter included the effect of the approximate 11% German price decrease of Esbriet, which became effective September 15, 2012. Esbriet was approved in Canada October 1, 2012 for the treatment of mild to moderate IPF and became commercially available on January 2, 2013.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters